Jiang Rensheng & family

01

Founder and chairman of Chongqing Zhifei Biological Products (Shenzhen: 300122), China's largest privately owned vaccine manufacturer; Zhifei produces vaccines for meningococcal disease, pneumococcal disease, HPV (Gardasil distributed under partnership with Merck), influenza, and other indications, distributed through China's National Immunization Program and private vaccination market. Jiang retains majority ownership; revenues reached ¥18B+ in 2022.

02

During the COVID-19 pandemic, Zhifei partnered with AstraZeneca to distribute the Oxford-AstraZeneca COVID-19 vaccine in China, and Zhifei independently developed Zifivax — a recombinant protein subunit COVID-19 vaccine — which received emergency authorization in multiple countries in 2021–2022. The company became one of the most prominent Chinese vaccine manufacturers during the global pandemic response; at peak valuation in 2021, Jiang's stake made him one of China's wealthiest individuals.

03

Zhifei's revenue model is structurally dependent on Chinese government health policy: whether a vaccine is included in the state-funded National Immunization Program (free to patients) versus the private-pay Category II market (where Zhifei earns premium margins) is determined by regulators. Zhifei has consistently lobbied for inclusion of its higher-margin vaccines in state-funded schedules, creating a business model that operates at the intersection of public health outcomes and private commercial incentives — a dynamic regulators and health economists have scrutinized.